Evidence map›Paper›PMID 19703394›Full record

ArticleCell2009

Widespread shortening of 3'UTRs by alternative cleavage and polyadenylation activates oncogenes in cancer cells.

Christine Mayr, David P Bartel

Open access · bronzeAbstract read
In one paragraph

Article in Cell, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1,044 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1,044citing papers in PubMed, 2 pooled it
32.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1,044 citing papers in PubMed, 2 syntheses or guidelines pooled it, 991 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article

984 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Christine MayrHoward Hughes Medical Institute, USA. mayrc@mskcc.org
David P Bartel
Howard Hughes Medical Institute · USMemorial Sloan Kettering Cancer Center · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
MicroRNAs and hematopoietic differentiationR01DK068348 · NIDDK · WHITEHEAD INSTITUTE FOR BIOMEDICAL RES · PI LODISH, HARVEY F · 2004 to 2019
$8.3M
MicroRNA genes and their functionsR01GM067031 · NIGMS · WHITEHEAD INSTITUTE FOR BIOMEDICAL RES · PI BARTEL, DAVID P · 2002 to 2015
$7.3M
Howard Hughes Medical InstituteNCI NIH HHS P30 CA008748NIDDK NIH HHS R01 DK068348NIGMS NIH HHS R01 GM067031
6 · The paper itself

Abstract

In cancer cells, genetic alterations can activate proto-oncogenes, thereby contributing to tumorigenesis. However, the protein products of oncogenes are sometimes overexpressed without alteration of the proto-oncogene. Helping to explain this phenomenon, we found that when compared to similarly proliferating nontransformed cell lines, cancer cell lines often expressed substantial amounts of mRNA isoforms with shorter 3' untranslated regions (UTRs). These shorter isoforms usually resulted from alternative cleavage and polyadenylation (APA). The APA had functional consequences, with the shorter mRNA isoforms exhibiting increased stability and typically producing ten-fold more protein, in part through the loss of microRNA-mediated repression. Moreover, expression of the shorter mRNA isoform of the proto-oncogene IGF2BP1/IMP-1 led to far more oncogenic transformation than did expression of the full-length, annotated mRNA. The high incidence of APA in cancer cells, with consequent loss of 3'UTR repressive elements, suggests a pervasive role for APA in oncogene activation without genetic alteration.

Indexed as

Alternative SplicingOncogenesPolyadenylation3' Untranslated RegionsCell Line, TumorCell Transformation, NeoplasticCyclin D2CyclinsGene Expression Regulation, NeoplasticHumansMutationProto-Oncogene MasRNA-Binding ProteinsRNA StabilityS Phase3' Untranslated RegionsCCND2 protein, humanCyclin D2CyclinsIGF2BP1 protein, humanMAS1 protein, humanProto-Oncogene MasRNA-Binding Proteins

Identifiers

PMID19703394
PMCPMC2819821
OpenAlexW1542927170

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.